27:@0.895357:0.033217:0.916054:0.033217:0.916054:0.013052:0.895357:0.013052:0.010348:0.010348
HANDBOOK OF GENERAL MEDICINE VOL 1:@0.649278:0.972666:0.923020:0.972666:0.923020:0.958637:0.649278:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
TREATMENT AppROACHEs:@0.983817:0.243404:0.983817:0.056389:0.958557:0.056389:0.958557:0.243404:0.008796:-0.015759:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.114251:0.006043:0.014598:-0.134892:0.158619:-0.158619:0.000000:0.000000:0.000000:0.000000:0.242661:0.009202
TREATMENT AppROACHEs:@0.397039:0.033156:0.624383:0.033156:0.624383:0.013866:0.397039:0.013866:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
ventricular fibrillation) and may be indicated in primary :@0.076190:0.084931:0.485130:0.084931:0.485130:0.069149:0.076190:0.069149:0.008376:0.009827:0.009223:0.005125:0.004551:0.003024:0.009782:0.009192:0.003024:0.010326:0.004551:0.004611:0.003681:0.003681:0.010311:0.004551:0.003024:0.003024:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.005579:0.004611:0.010326:0.009223:0.010357:0.004611:0.014182:0.010326:0.008104:0.004611:0.010311:0.009827:0.004611:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.009827:0.010357:0.004611:0.003024:0.009223:0.004611:0.010311:0.004551:0.003024:0.014182:0.010326:0.004551:0.008104:0.004188
and secondary prevention scenarios. :@0.076190:0.099040:0.352733:0.099040:0.352733:0.083257:0.076190:0.083257:0.010326:0.009223:0.010357:0.004188:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.010326:0.004551:0.008104:0.004188:0.010311:0.004551:0.009827:0.008376:0.009827:0.009223:0.005125:0.003024:0.009903:0.009223:0.004188:0.005866:0.009782:0.009827:0.009223:0.010326:0.004551:0.003024:0.009903:0.005866:0.004188:0.004188
Left  ventricular  assisting devices and cardiac trans-:@0.090478:0.113148:0.480942:0.113148:0.480942:0.097366:0.090478:0.097366:0.006985:0.009827:0.004747:0.005125:0.004188:0.002978:0.008376:0.009827:0.009223:0.005125:0.004551:0.003024:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188:0.002978:0.010326:0.005866:0.005866:0.003024:0.005866:0.005125:0.003024:0.009223:0.010175:0.007182:0.010357:0.009827:0.008376:0.003024:0.009782:0.009827:0.005866:0.007182:0.010326:0.009223:0.010357:0.007182:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.009782:0.007182:0.005125:0.004551:0.010326:0.009223:0.005866:0.005020
plantation are alternatives for bridging and destination :@0.076190:0.127257:0.485130:0.127257:0.485130:0.111474:0.076190:0.111474:0.010311:0.003024:0.010326:0.009223:0.005125:0.010326:0.005125:0.003024:0.009903:0.009223:0.004808:0.010326:0.004551:0.009827:0.004808:0.010326:0.003024:0.005125:0.009827:0.004551:0.009223:0.010326:0.005125:0.003024:0.008376:0.009827:0.005866:0.004808:0.004747:0.009903:0.004551:0.004808:0.010311:0.004551:0.003024:0.010357:0.010175:0.003024:0.009223:0.010175:0.004808:0.010326:0.009223:0.010357:0.004808:0.010357:0.009827:0.005866:0.005125:0.003024:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188
therapy respectively.:@0.076190:0.141365:0.229679:0.141365:0.229679:0.125583:0.076190:0.125583:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.004551:0.009827:0.005866:0.010311:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.003024:0.008104:0.004188
ADDitiOnAl nOtes:@0.076190:0.174234:0.246196:0.174234:0.246196:0.154069:0.076190:0.154069:0.013674:0.012935:0.012935:0.005174:0.007761:0.005174:0.015522:0.013674:0.013674:0.008131:0.005174:0.013674:0.015522:0.007761:0.009609:0.009609
The  use of n-3 polyunsaturated fatty acids (n-3-pUFA) :@0.076190:0.190123:0.485145:0.190123:0.485145:0.174340:0.076190:0.174340:0.006441:0.009223:0.009827:0.004188:0.002616:0.009192:0.005866:0.009827:0.006819:0.009903:0.004747:0.006819:0.009223:0.005020:0.008376:0.006819:0.010311:0.009903:0.003024:0.008104:0.009192:0.009223:0.005866:0.010326:0.005125:0.009192:0.004551:0.010326:0.005125:0.009827:0.010357:0.006819:0.004747:0.010326:0.005125:0.005125:0.008104:0.006819:0.010326:0.009782:0.003024:0.010357:0.005866:0.006819:0.005579:0.009223:0.005020:0.008376:0.005019:0.008950:0.009903:0.007333:0.011188:0.005579:0.004188
may be considered in the symptomatic heart-failure :@0.076190:0.204232:0.485130:0.204232:0.485130:0.188449:0.076190:0.188449:0.014182:0.010326:0.008104:0.008028:0.010311:0.009827:0.008028:0.009782:0.009903:0.009223:0.005866:0.003024:0.010357:0.009827:0.004551:0.009827:0.010357:0.008028:0.003024:0.009223:0.008028:0.005125:0.009223:0.009827:0.008028:0.005866:0.008104:0.014182:0.010311:0.005125:0.009903:0.014182:0.010326:0.005125:0.003024:0.009782:0.008028:0.009223:0.009827:0.010326:0.004551:0.005125:0.005020:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188
patient to reduce the risk of cardiovascular hospitalisa-:@0.076190:0.218340:0.480957:0.218340:0.480957:0.202558:0.076190:0.202558:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.004703:0.005125:0.009903:0.004702:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.004702:0.005125:0.009223:0.009827:0.004702:0.004551:0.003024:0.005866:0.007590:0.004702:0.009903:0.004747:0.004702:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004717:0.009223:0.009903:0.005866:0.010311:0.003024:0.005125:0.010326:0.003024:0.003024:0.005866:0.010357:0.568332
tion and death, against a background of optimal anti-:@0.076190:0.232449:0.480942:0.232449:0.480942:0.216666:0.076190:0.216666:0.005125:0.003024:0.009903:0.009223:0.004929:0.010326:0.009223:0.010357:0.004929:0.010357:0.009827:0.010326:0.005125:0.009223:0.004188:0.004929:0.010326:0.010175:0.010326:0.003024:0.009223:0.005866:0.005125:0.004944:0.010326:0.004929:0.010311:0.010326:0.009782:0.007590:0.010175:0.004551:0.009903:0.009192:0.009223:0.010357:0.004929:0.009903:0.004747:0.004929:0.009903:0.010311:0.005125:0.003024:0.014182:0.010326:0.003024:0.004944:0.010326:0.009223:0.005125:0.003024:0.005020
failure therapy.:@0.076190:0.246557:0.186726:0.246557:0.186726:0.230775:0.076190:0.230775:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188
Antiplatelet  therapy  offers  no benefit to the patient :@0.090478:0.260666:0.485115:0.260666:0.485115:0.244883:0.090478:0.244883:0.011188:0.009223:0.005125:0.003024:0.010311:0.003024:0.010326:0.005125:0.009827:0.003024:0.009827:0.005125:0.004188:0.002283:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.002283:0.009903:0.004747:0.004747:0.009827:0.004551:0.005866:0.004188:0.002268:0.009223:0.009903:0.006456:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.006456:0.005125:0.009903:0.006456:0.005125:0.009223:0.009827:0.006456:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.004188
with heart failure, in the absence of associated coro-:@0.076190:0.274774:0.480957:0.274774:0.480957:0.258992:0.076190:0.258992:0.012564:0.003024:0.005125:0.009223:0.006395:0.009223:0.009827:0.010326:0.004551:0.005125:0.006380:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.006380:0.003024:0.009223:0.006395:0.005125:0.009223:0.009827:0.006380:0.010326:0.010311:0.005866:0.009827:0.009223:0.009782:0.009827:0.006380:0.009903:0.004747:0.006380:0.010326:0.005866:0.005866:0.009903:0.009782:0.003024:0.010326:0.005125:0.009827:0.010357:0.006395:0.009782:0.009903:0.004551:0.009918:0.005020
nary artery disease. Likewise, anticoagulation, in the ab-:@0.076190:0.288883:0.480942:0.288883:0.480942:0.273100:0.076190:0.273100:0.009223:0.010326:0.004551:0.008104:0.003417:0.010326:0.004551:0.005125:0.009827:0.004551:0.008104:0.003417:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188:0.003417:0.006985:0.003024:0.007590:0.009827:0.012564:0.003024:0.005866:0.009827:0.004188:0.003417:0.010326:0.009223:0.005125:0.003024:0.009782:0.009903:0.010326:0.010175:0.009192:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.003417:0.003024:0.009223:0.003417:0.005125:0.009223:0.009827:0.003417:0.010326:0.010311:0.005020
sence of atrial fibrillation/flutter, and active ventricular :@0.076190:0.302991:0.485145:0.302991:0.485145:0.287209:0.076190:0.287209:0.005866:0.009827:0.009223:0.009782:0.009827:0.005836:0.009903:0.004747:0.005836:0.010326:0.005125:0.004551:0.003024:0.010326:0.003024:0.005836:0.003681:0.003681:0.010311:0.004551:0.003024:0.003024:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.006607:0.003666:0.003666:0.009192:0.005125:0.005125:0.009827:0.004551:0.004188:0.005821:0.010326:0.009223:0.010357:0.005836:0.010326:0.009782:0.005125:0.003024:0.008376:0.009827:0.005836:0.008376:0.009827:0.009223:0.005125:0.004551:0.003024:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188
or atrial thrombus, has no effect in reducing morbidity :@0.076190:0.317100:0.485145:0.317100:0.485145:0.301317:0.076190:0.301317:0.009903:0.004551:0.005730:0.010326:0.005125:0.004551:0.003024:0.010326:0.003024:0.005730:0.005125:0.009223:0.004551:0.009903:0.014182:0.010311:0.009192:0.005866:0.004188:0.005730:0.009223:0.010326:0.005866:0.005730:0.009223:0.009903:0.005730:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005730:0.003024:0.009223:0.005730:0.004551:0.009827:0.010357:0.009192:0.009782:0.003024:0.009223:0.010175:0.005730:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.003024:0.005125:0.008104:0.004188
and mortality, compared with placebo or aspirin. :@0.076190:0.331209:0.440589:0.331209:0.440589:0.315426:0.076190:0.315426:0.010326:0.009223:0.010357:0.004188:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.004188:0.004188:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.004188:0.012564:0.003024:0.005125:0.009223:0.004188:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.004188:0.009903:0.004551:0.004188:0.010326:0.005866:0.010311:0.003024:0.004551:0.003024:0.009223:0.004188:0.004188
Long-acting calcium-channel blockers, e.g. diltiazem :@0.090478:0.345317:0.485130:0.345317:0.485130:0.329534:0.090478:0.329534:0.006985:0.009903:0.009223:0.010175:0.005020:0.010326:0.009782:0.005125:0.003024:0.009223:0.010175:0.004445:0.009782:0.010326:0.003024:0.009782:0.003024:0.009192:0.014182:0.005020:0.009782:0.009223:0.010326:0.009223:0.009223:0.009827:0.003024:0.004460:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.004188:0.004460:0.009827:0.004188:0.010175:0.004188:0.004445:0.010357:0.003024:0.003024:0.005125:0.003024:0.010326:0.006426:0.009827:0.014182:0.004188
and verapamil, should be avoided (negatively inotrop-:@0.076190:0.359426:0.480957:0.359426:0.480957:0.343643:0.076190:0.343643:0.010326:0.009223:0.010357:0.004521:0.008376:0.009827:0.004551:0.010326:0.010311:0.010326:0.014182:0.003024:0.003039:0.004188:0.004521:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004521:0.010311:0.009827:0.004536:0.010326:0.008376:0.009903:0.003024:0.010357:0.009827:0.010357:0.004536:0.005579:0.009223:0.009827:0.010175:0.010326:0.005125:0.003024:0.008376:0.009827:0.003024:0.008104:0.004536:0.003024:0.009223:0.009903:0.005125:0.004551:0.009903:0.010311:0.005020
ic) in patients with heart failure with reduced ejection :@0.076190:0.373534:0.485145:0.373534:0.485145:0.357751:0.076190:0.357751:0.003024:0.009782:0.005579:0.006002:0.003024:0.009223:0.006002:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006002:0.012564:0.003024:0.005125:0.009223:0.006002:0.009223:0.009827:0.010326:0.004551:0.005125:0.006002:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.006002:0.012564:0.003024:0.005125:0.009223:0.006002:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.006002:0.009827:0.003069:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188
fraction. Amlodipine is safe in patients with heart failure. :@0.076190:0.387643:0.485130:0.387643:0.485130:0.371860:0.076190:0.371860:0.004747:0.004551:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.003901:0.011188:0.014182:0.003024:0.009903:0.010357:0.003024:0.010311:0.003024:0.009223:0.009827:0.003901:0.003024:0.005866:0.003916:0.005866:0.010326:0.004747:0.009827:0.003901:0.003024:0.009223:0.003901:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003901:0.012564:0.003024:0.005125:0.009223:0.003901:0.009223:0.009827:0.010326:0.004551:0.005125:0.003901:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.004188
Felodipine would be a secondary alternative.:@0.076190:0.401751:0.409369:0.401751:0.409369:0.385969:0.076190:0.385969:0.007333:0.009827:0.003024:0.009903:0.010357:0.003024:0.010311:0.003024:0.009223:0.009827:0.004188:0.012564:0.009903:0.009192:0.003024:0.010357:0.004188:0.010311:0.009827:0.004188:0.010326:0.004188:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.010326:0.004551:0.008104:0.004188:0.010326:0.003024:0.005125:0.009827:0.004551:0.009223:0.010326:0.005125:0.003024:0.008376:0.009827:0.004188
referenCes:@0.076190:0.434648:0.182628:0.434648:0.182628:0.414483:0.076190:0.414483:0.010718:0.009609:0.008870:0.009609:0.010718:0.009609:0.013674:0.014413:0.009609:0.009609
1. :@0.076190:0.446542:0.088985:0.446542:0.088985:0.434267:0.076190:0.434267:0.006397:0.003140:0.003257
McMurray JJV, packer M, Desai As, :@0.101390:0.446542:0.297511:0.446542:0.297511:0.434267:0.101390:0.434267:0.010689:0.007491:0.010689:0.007032:0.003422:0.003422:0.007914:0.006185:0.002528:0.005550:0.005550:0.008137:0.003140:0.002528:0.006844:0.007914:0.007491:0.005786:0.007526:0.003422:0.002528:0.010689:0.003140:0.002516:0.008631:0.007526:0.004445:0.007914:0.002234:0.002516:0.008584:0.005739:0.003140:0.003257
et al:@0.296759:0.446542:0.320936:0.446542:0.320936:0.434267:0.296759:0.434267:0.007526:0.003869:0.002516:0.007914:0.002352
. Baseline characteristics and :@0.320818:0.446542:0.484189:0.446542:0.484189:0.434267:0.320818:0.434267:0.003140:0.002528:0.006632:0.007914:0.004445:0.007526:0.002234:0.002234:0.007056:0.007526:0.002516:0.007491:0.007056:0.007914:0.003422:0.007914:0.007491:0.003869:0.007526:0.003422:0.002234:0.004445:0.003869:0.002234:0.007491:0.004445:0.002516:0.007914:0.007056:0.008055:0.003257
treatment of patients in prospective comparison of ARNI with ACEI to :@0.101390:0.457444:0.484201:0.457444:0.484201:0.445168:0.101390:0.445168:0.003869:0.003422:0.007526:0.007914:0.003869:0.010913:0.007526:0.007056:0.003869:0.002646:0.007585:0.003575:0.002646:0.007902:0.007914:0.003869:0.002234:0.007526:0.007056:0.003869:0.004445:0.002646:0.002234:0.007056:0.002646:0.007902:0.003422:0.007585:0.004445:0.007902:0.007526:0.007491:0.003869:0.002234:0.006397:0.007526:0.002646:0.007491:0.007585:0.010913:0.007902:0.007914:0.003422:0.002234:0.004445:0.007585:0.007056:0.002646:0.007585:0.003575:0.002646:0.008584:0.007020:0.008584:0.002540:0.002646:0.009654:0.002234:0.003869:0.007056:0.002646:0.008584:0.009443:0.006185:0.002540:0.002646:0.003869:0.007702:0.003257
determine impact on global mortality and morbidity in heart failure:@0.101390:0.468345:0.480967:0.468345:0.480967:0.456070:0.101390:0.456070:0.007937:0.007526:0.003869:0.007526:0.003422:0.010913:0.002234:0.007056:0.007526:0.003822:0.002234:0.010913:0.007902:0.007914:0.007491:0.003869:0.003822:0.007585:0.007056:0.003822:0.007796:0.002234:0.007585:0.007902:0.007914:0.002234:0.003822:0.010913:0.007585:0.003422:0.003869:0.007914:0.002234:0.002234:0.003869:0.006185:0.003822:0.007914:0.007056:0.007937:0.003822:0.010913:0.007585:0.003422:0.007902:0.002234:0.007937:0.002234:0.003869:0.006185:0.003822:0.002234:0.007056:0.003822:0.007056:0.007526:0.007914:0.003422:0.003869:0.003822:0.003575:0.007914:0.002234:0.002234:0.007032:0.003422:0.007644
trial (pARADIGM-HF). :@0.101390:0.479247:0.219359:0.479247:0.219359:0.466971:0.101390:0.466971:0.003869:0.003422:0.002234:0.007914:0.002234:0.003140:0.004222:0.006844:0.008584:0.007020:0.008584:0.008631:0.002540:0.010136:0.010689:0.003786:0.007914:0.005586:0.004222:0.003140:0.003257
Eur J Heart Fail:@0.219242:0.479247:0.299581:0.479247:0.299581:0.466971:0.219242:0.466971:0.006185:0.007032:0.003422:0.003140:0.005550:0.003140:0.007914:0.007526:0.007914:0.003422:0.003869:0.003140:0.005586:0.007914:0.002234:0.002352
. 2014;16(7):817-825.:@0.299463:0.479247:0.410671:0.479247:0.410671:0.466971:0.299463:0.466971:0.003140:0.003140:0.006397:0.006397:0.006397:0.006397:0.003140:0.006397:0.006397:0.004222:0.006397:0.004222:0.003140:0.006397:0.006397:0.006397:0.003786:0.006397:0.006397:0.006397:0.003257
2.:@0.076190:0.490148:0.085962:0.490148:0.085962:0.477873:0.076190:0.477873:0.006515:0.003257
McMurray JJV, packer M, Desai As, :@0.101390:0.490148:0.302450:0.490148:0.302450:0.477873:0.101390:0.477873:0.010807:0.007608:0.010807:0.007150:0.003540:0.003540:0.008032:0.006303:0.002846:0.005668:0.005668:0.008255:0.003257:0.002857:0.006961:0.008032:0.007608:0.005903:0.007644:0.003540:0.002846:0.010807:0.003257:0.002857:0.008749:0.007644:0.004563:0.008032:0.002352:0.002857:0.008702:0.005856:0.003257:0.003257
et al:@0.302050:0.490148:0.326921:0.490148:0.326921:0.477873:0.302050:0.477873:0.007644:0.003986:0.002857:0.008032:0.002352
. Angiotensin-neprilysin inhi-:@0.326921:0.490148:0.480956:0.490148:0.480956:0.477873:0.326921:0.477873:0.003257:0.002857:0.008702:0.007173:0.007914:0.002352:0.007702:0.003986:0.007644:0.007173:0.004563:0.002352:0.007173:0.003904:0.007173:0.007644:0.008020:0.003540:0.002352:0.002352:0.006303:0.004563:0.002352:0.007173:0.002857:0.002352:0.007173:0.007173:0.002352:0.003904
bition versus enalapril in heart failure. :@0.101390:0.501050:0.308330:0.501050:0.308330:0.488774:0.101390:0.488774:0.008020:0.002352:0.003986:0.002352:0.007702:0.007173:0.002140:0.006515:0.007644:0.003540:0.004563:0.007150:0.004563:0.002140:0.007644:0.007173:0.008032:0.002352:0.008032:0.008020:0.003540:0.002352:0.002352:0.002152:0.002352:0.007173:0.002140:0.007173:0.007644:0.008032:0.003540:0.003986:0.002140:0.003692:0.008032:0.002352:0.002352:0.007150:0.003540:0.007644:0.003257:0.003257
N Engl J Med:@0.307213:0.501050:0.378250:0.501050:0.378250:0.488774:0.307213:0.488774:0.008702:0.002140:0.006303:0.007173:0.007914:0.002352:0.002140:0.005668:0.002140:0.010807:0.007644:0.008055
. 2014;371(11):993-:@0.378250:0.501050:0.480920:0.501050:0.480920:0.488774:0.378250:0.488774:0.003257:0.002140:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904
1004.:@0.101390:0.511951:0.130706:0.511951:0.130706:0.499676:0.101390:0.499676:0.006515:0.006515:0.006515:0.006515:0.003257
3.:@0.076190:0.522853:0.085962:0.522853:0.085962:0.510577:0.076190:0.510577:0.006515:0.003257
Entresto [prescribing information]. East Hanover, NJ: Novartis phar-:@0.101390:0.522853:0.480956:0.522853:0.480956:0.510577:0.101390:0.510577:0.006303:0.007173:0.003986:0.003540:0.007644:0.004563:0.003986:0.007702:0.004033:0.004127:0.008020:0.003540:0.007644:0.004563:0.007608:0.003540:0.002352:0.008020:0.002352:0.007173:0.007914:0.004045:0.002352:0.007173:0.003692:0.007702:0.003540:0.011030:0.008032:0.003986:0.002352:0.007702:0.007173:0.004127:0.003257:0.004033:0.006303:0.008032:0.004563:0.003986:0.004045:0.008032:0.008032:0.007173:0.007702:0.006515:0.007644:0.003540:0.003257:0.004045:0.008702:0.005668:0.003257:0.004045:0.008702:0.007702:0.006515:0.008032:0.003540:0.003986:0.002352:0.004563:0.004045:0.006961:0.007173:0.008032:0.003540:0.003904
maceuticals Corp; November 2017.:@0.101390:0.533754:0.303708:0.533754:0.303708:0.521479:0.101390:0.521479:0.011030:0.008032:0.007608:0.007644:0.007150:0.003986:0.002352:0.007608:0.008032:0.002352:0.004563:0.003257:0.009560:0.007702:0.003540:0.008020:0.003257:0.003257:0.008702:0.007702:0.006515:0.007644:0.011030:0.008020:0.007644:0.003540:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257
furtHer reADinG:@0.076190:0.567421:0.234739:0.567421:0.234739:0.547256:0.076190:0.547256:0.008870:0.011826:0.010718:0.007761:0.012566:0.009609:0.010718:0.005174:0.010718:0.009609:0.013674:0.012935:0.005174:0.013674:0.015522
-  Yancy CW, Jessup M, Bozkurt B, :@0.076190:0.579315:0.276791:0.579315:0.276791:0.567040:0.076190:0.567040:0.003904:0.003257:0.007961:0.006961:0.008032:0.007173:0.007608:0.006303:0.004069:0.009560:0.011289:0.003257:0.004069:0.005668:0.007644:0.004563:0.004563:0.007150:0.008020:0.004069:0.010807:0.003257:0.004069:0.006750:0.007702:0.004998:0.005903:0.007150:0.003540:0.003986:0.004057:0.006750:0.003257:0.003257
et al:@0.277603:0.579315:0.303685:0.579315:0.303685:0.567040:0.277603:0.567040:0.007644:0.003986:0.004069:0.008032:0.002352
. 2013 ACCF/AHA guideline for :@0.303685:0.579315:0.484201:0.579315:0.484201:0.567040:0.303685:0.567040:0.003257:0.004069:0.006515:0.006515:0.006515:0.006515:0.004080:0.008702:0.009560:0.009560:0.005703:0.005139:0.008702:0.008032:0.008702:0.004057:0.007914:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.004069:0.003692:0.007702:0.003540:0.003257
the management of heart failure: A report of the American College :@0.091313:0.590217:0.484201:0.590217:0.484201:0.577941:0.091313:0.577941:0.003986:0.007173:0.007644:0.003681:0.011030:0.008032:0.007173:0.008032:0.007914:0.007644:0.011030:0.007644:0.007173:0.003986:0.003681:0.007702:0.003692:0.003681:0.007173:0.007644:0.008032:0.003540:0.003986:0.003681:0.003692:0.008032:0.002352:0.002352:0.007150:0.003540:0.007644:0.003257:0.003681:0.008702:0.003681:0.003540:0.007644:0.008020:0.007702:0.003540:0.003986:0.003681:0.007702:0.003692:0.003681:0.003986:0.007173:0.007644:0.003681:0.008702:0.011030:0.007644:0.003540:0.002352:0.007608:0.008032:0.007173:0.003681:0.009560:0.007702:0.002352:0.002352:0.007644:0.007914:0.007644:0.003257
of Cardiology Foundation/American Heart Association Task Force on :@0.091313:0.601118:0.484225:0.601118:0.484225:0.588843:0.091313:0.588843:0.007702:0.003692:0.003140:0.009560:0.008032:0.003540:0.008055:0.002352:0.007702:0.002352:0.007702:0.007914:0.006303:0.003140:0.005703:0.007702:0.007150:0.007173:0.008055:0.008032:0.003986:0.002352:0.007702:0.007173:0.005139:0.008702:0.011030:0.007644:0.003540:0.002352:0.007608:0.008032:0.007173:0.003128:0.008032:0.007644:0.008032:0.003540:0.003986:0.003140:0.008702:0.004563:0.004563:0.007702:0.007608:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173:0.003140:0.005009:0.008032:0.004563:0.005903:0.003140:0.005703:0.007702:0.003540:0.007608:0.007644:0.003128:0.007702:0.007173:0.003257
practice Guidelines. :@0.091313:0.612019:0.208353:0.612019:0.208353:0.599744:0.091313:0.599744:0.006961:0.003540:0.008032:0.007608:0.003986:0.002352:0.007608:0.007644:0.003257:0.010254:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.004563:0.003257:0.003257
Circulation:@0.208353:0.612019:0.270159:0.612019:0.270159:0.599744:0.208353:0.599744:0.009560:0.002352:0.003540:0.007608:0.007150:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173
. 2013;128(16):e240-e327.:@0.270159:0.612019:0.412035:0.612019:0.412035:0.599744:0.270159:0.599744:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.004339:0.003257:0.007644:0.006515:0.006515:0.006515:0.003904:0.007644:0.006515:0.006515:0.006515:0.003257
-  European society of Cardiology. :@0.076190:0.622921:0.283823:0.622921:0.283823:0.610646:0.076190:0.610646:0.003904:0.003257:0.007961:0.006303:0.007150:0.003540:0.007702:0.008020:0.007644:0.008032:0.007173:0.004692:0.005856:0.007702:0.007608:0.002352:0.007644:0.003986:0.006303:0.004692:0.007702:0.003692:0.004692:0.009560:0.008032:0.003540:0.008055:0.002352:0.007702:0.002352:0.007702:0.007914:0.006303:0.003257:0.229303
Clinical Practice Guidelines:@0.285258:0.622921:0.443702:0.622921:0.443702:0.610646:0.285258:0.610646:0.009560:0.002352:0.002352:0.007173:0.002352:0.007608:0.008032:0.002352:0.004704:0.006961:0.003540:0.008032:0.007608:0.003986:0.002352:0.007608:0.007644:0.004692:0.010254:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.004563
. 2018. :@0.443702:0.622921:0.484225:0.622921:0.484225:0.610646:0.443702:0.610646:0.003257:0.004692:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257
https://www.escardio.org/Guidelines/Clinical-practice-Guidelines:@0.091313:0.633822:0.463728:0.633822:0.463728:0.621547:0.091313:0.621547:0.007173:0.003986:0.003986:0.008020:0.004563:0.003257:0.005139:0.005139:0.009772:0.009772:0.009772:0.003257:0.007644:0.004563:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.003257:0.007702:0.003540:0.007914:0.005139:0.010254:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.004563:0.005139:0.009560:0.002352:0.002352:0.007173:0.002352:0.007608:0.008032:0.002352:0.003904:0.006961:0.003540:0.008032:0.007608:0.003986:0.002352:0.007608:0.007644:0.003904:0.010254:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.004563